Bortezomib, a proteasome inhibitor that indirectly inhibits the NF-κB pathway, has been shown to impair the viability and induce apoptosis of NKTCL cell lines [94]. The gene discussed is NFKB1; the disease is extranodal nasal NK/T cell lymphoma.